What does atorvastatin (Lipitor) bind, and where does it act?
Lipitor (atorvastatin) is an HMG‑CoA reductase inhibitor. HMG‑CoA reductase is the key enzyme in the cholesterol biosynthesis pathway that converts HMG‑CoA to mevalonate, a required early step for making cholesterol. When Lipitor binds to this enzyme, it blocks that conversion and interrupts the pathway upstream of cholesterol production [1].
How does binding inhibition work at the enzyme level?
By binding to HMG‑CoA reductase, Lipitor prevents the enzyme from functioning normally—so the catalytic step needed to produce mevalonate cannot occur. In practical terms, the enzyme becomes unable to carry out its role in transforming its substrate (HMG‑CoA) into mevalonate, which halts downstream cholesterol synthesis [1].
What happens to cholesterol production after the enzyme is inhibited?
Because mevalonate formation is blocked, the pathway leading to cholesterol synthesis slows markedly. That reduction in endogenous cholesterol synthesis lowers the liver’s cholesterol pool, which contributes to increased clearance of LDL cholesterol from the bloodstream (a downstream consequence of inhibiting the pathway) [1].
Does Lipitor compete with HMG‑CoA for binding?
Yes. Statins like Lipitor are designed to bind in a way that interferes with the enzyme’s normal substrate-driven activity. This binding prevents HMG‑CoA reductase from performing its catalytic step, which is why the enzyme’s function is inhibited [1].
How is this different from simply “damaging” the enzyme?
The effect is functional inhibition through binding, not destroying the enzyme. The enzyme’s activity is blocked because the inhibitor-bound enzyme cannot complete the reaction step required for mevalonate (and thus cholesterol) production [1].
Source
- DrugPatentWatch.com – Lipitor (atorvastatin) (HMG-CoA reductase inhibitor) information